Molecular evolution is the process of simulating the natural evolution of molecules in chemical space to explore potential molecular structures and properties. The relationships between similar molecules are often described through transformations such as adding, deleting, and modifying atoms and chemical bonds, reflecting specific evolutionary paths. Existing molecular representation methods mainly focus on mining data, such as atomic-level structures and chemical bonds directly from the molecules, often overlooking their evolutionary history. Consequently, we aim to explore the possibility of enhancing molecular representations by simulating the evolutionary process. We extract and analyze the changes in the evolutionary pathway and explore combining it with existing molecular representations. Therefore, this paper proposes the molecular evolutionary network (MEvoN) for molecular representations. First, we construct the MEvoN using molecules with a small number of atoms and generate evolutionary paths utilizing similarity calculations. Then, by modeling the atomic-level changes, MEvoN reveals their impact on molecular properties. Experimental results show that the MEvoN-based molecular property prediction method significantly improves the performance of traditional end-to-end algorithms by approximately 33% on both the QM7 and QM9 datasets.

The prediction of compound–protein interactions (CPIs) is crucial for drug discovery. Most existing CPI prediction models rely on protein sequence information as input. However, in early-stage drug development, particularly in phenotype-driven studies or compound-response analyses, proteins are often annotated only with functional labels, and their sequences remain undetermined. Consequently, current methods are inapplicable in such scenarios. Furthermore, our experiments find that even when large-scale perturbations were applied to protein sequences, the predictive performance of the existing models did not show a significant decline. It indicates that the high investment in sequencing may not bring corresponding returns. To address the above issues, we propose an inexpensive, protein-sequencing-free framework BioText-CPI, based on the Biomedical Textual description of protein for CPI prediction. Firstly, during the pre-training stage of the model, we use contrastive learning to align protein texts and sequence modalities. Subsequently, we add biological text descriptions of proteins to the existing public CPI dataset to construct a new CPI dataset. Finally, in the CPI prediction stage, the sequence and biomedical text descriptions of proteins can be used as the input for CPI prediction either separately or simultaneously to meet the application requirements of different scenarios. The experiments demonstrate that BioText-CPI achieves comparable effects to the traditional methods when only the biomedical description of protein is input. Moreover, when the two modalities of protein information are input simultaneously, BioText-CPI achieves state-of-the-art performance across multiple scenarios.

Antibody design remains a critical challenge in therapeutic and diagnostic development, particularly for complex antigens with diverse binding interfaces. Current computational methods face two main limitations: (1) capturing geometric features while preserving symmetries, and (2) generalizing novel antigen interfaces. Despite recent advancements, these methods often fail to accurately capture molecular interactions and maintain structural integrity. To address these challenges, we propose AbMEGD, an end-to-end framework integrating Multi-scale Equivariant Graph Diffusion for antibody sequence and structure co-design. Leveraging advanced geometric deep learning, AbMEGD combines atomic-level geometric features with residue-level embeddings, capturing local atomic details and global sequence-structure interactions. Its E(3)-equivariant diffusion method ensures geometric precision, computational efficiency, and robust generalizability for complex antigens. Furthermore, experiments using the SAbDab database demonstrate a 10.13% increase in amino acid recovery, 3.32% rise in improvement percentage, and a 0.062 Å reduction in root mean square deviation within the critical CDR-H3 region compared to DiffAb, a leading antibody design model. These results highlight AbMEGD's ability to balance structural integrity with improved functionality, establishing a new benchmark for sequence-structure co-design and affinity optimization. The code is available at: https://github.com/Patrick221215/AbMEGD.